Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China.
Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China.
Crit Rev Oncol Hematol. 2016 Apr;100:137-40. doi: 10.1016/j.critrevonc.2016.02.006. Epub 2016 Feb 12.
Targeting kinase inhibitors (TKIs) are effective tools for treating advanced cancer. However, acquired resistance represents a roadblock in the use of TKIs, such as sorafenib, for cancer therapy. Understanding the acquisition of resistance to sorafenib will help doctors to cope with acquired resistance to TKIs in general and to develop personalized medicine strategies for cancer patients. Autophagy is a biological process that occurs in normal organisms. However, it is also a component of multiple disease processes, including cancer development and progression. However, the roles of autophagy in cancer and in response to cancer therapy are controversial. In this review, we summarize the progress in autophagy and sorafenib resistance research, which is representative of acquired resistance to targeted cancer therapy.
靶向激酶抑制剂（TKIs）是治疗晚期癌症的有效工具。然而，获得性耐药是 TKI（如索拉非尼）在癌症治疗中应用的障碍。了解对索拉非尼的耐药性获得将有助于医生应对 TKI 的获得性耐药性，并为癌症患者制定个性化的医学策略。自噬是一种在正常生物体中发生的生物学过程。然而，它也是多种疾病过程的组成部分，包括癌症的发展和进展。然而，自噬在癌症中的作用以及对癌症治疗的反应是有争议的。在这篇综述中，我们总结了自噬和索拉非尼耐药性研究的进展，这是针对靶向癌症治疗的获得性耐药性的代表性研究。
